Keyphrases
Open Globe Injury
96%
Triamcinolone Acetonide
82%
Bevacizumab
78%
Intravitreal
71%
Corneal Endothelial Cells
64%
Retinal Ganglion Cell Loss
64%
Injury Model
64%
Resveratrol
64%
Ischemia-reperfusion Injury
64%
Conjunctival Autograft
64%
Conjunctival
64%
Platelet-rich Fibrin Membrane
64%
Treatment Group
61%
Endothelial Cell Density
45%
Phacoemulsification
45%
Type I Collagen
44%
Collagen Expression
44%
Inflammation
43%
Diabetic Retinopathy
43%
Rabbit Eye
39%
Proliferative Vitreoretinopathy
38%
Caspase-3 Expression
38%
Retinal Ganglion Cells
37%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
35%
Wound Healing
35%
Corticosteroids
35%
Intraocular Pressure
32%
Intravitreal Ranibizumab
32%
Structural Recovery
32%
Limbal Stem Cells
32%
Intracameral Injection
32%
Intravitreal Administration
32%
Eye Health
32%
Peripheral Arterial Stiffness
32%
Diabetic Macular Edema
32%
Intravitreal Triamcinolone Acetonide Injection
32%
MicroRNA
32%
Type 2 Diabetes Mellitus (T2DM)
32%
Na +
32%
Neuroprotective Agents
32%
Collagen Type 1
32%
Collagen Type I
32%
Penetrating Injury
32%
Matrix Metalloproteinases
32%
Hypothermic Perfusion
32%
Renal Impairment
32%
Mean Platelet Volume
32%
Platelet Distribution Width
32%
Transforming Growth Factor-β
32%
Plasminogen Activator inhibitor-1 (PAI-1)
32%
Medicine and Dentistry
Treatment Group
67%
Bevacizumab
64%
Triamcinolone Acetonide
64%
Collagen Type 1
64%
Autograft
64%
Platelet-Rich Fibrin
64%
Diabetic Retinopathy
61%
Cell Density
59%
Endothelial Cell
53%
Tumor Necrosis Factor
51%
Caspase 3
47%
Phacoemulsification
43%
Ganglion
36%
Wound Healing
32%
Penetrating Trauma
32%
Platelet
32%
Cell Loss
32%
Sodium Ion
32%
Endothelium Cell
32%
Adenosine Triphosphatase (Potassium)
32%
Matrix Metalloproteinase
32%
Mean Platelet Volume
32%
Arterial Stiffness
32%
Reperfusion Injury
32%
Corneal Endothelium
32%
Mesenchymal Stem Cell
32%
Maturity Onset Diabetes of the Young
32%
Resveratrol
32%
Antiapoptotic
32%
Intraocular Pressure
32%
Glutathione Reductase
32%
Central Retinal Artery Occlusion
32%
Superoxide Dismutase
32%
Interleukin-1
32%
Gliadin
32%
Interleukin 4
32%
Cell Count
32%
Coats' Disease
32%
Strabismus Surgery
32%
Asiatic Acid
32%
Eosinophil
32%
Dexamethasone
32%
Hyperglycemia
25%
Balanced Salt Solution
22%
Gelatinase A
21%
Metalloprotease Inhibitor
21%
Retinal Telangiectasia
21%
Intravitreal Administration
19%
Phosphate Buffered Saline
19%
Vasculotropin
19%
Pharmacology, Toxicology and Pharmaceutical Science
Triamcinolone Acetonide
100%
Bevacizumab
100%
Vasculotropin
72%
Reperfusion Injury
64%
Resveratrol
64%
Leporidae
63%
Intravitreal Administration
54%
Diabetic Retinopathy
53%
Tumor Necrosis Factor
51%
New Zealand Rabbit
42%
Vitreoretinopathy
41%
Treatment Group
40%
Inflammation
40%
Neuroprotective Agent
38%
Dexamethasone
35%
Penetrating Trauma
32%
Proliferative Diabetic Retinopathy
32%
Antiapoptotic
32%
Diabetic Macular Edema
32%
microRNA
32%
Matrix Metalloproteinase
32%
Plasminogen Activator Inhibitor 1
32%
microRNA 126
32%
Transforming Growth Factor Beta
32%
Collagen Type 1
32%
Platelet-Rich Fibrin
32%
Experimental Animal
32%
Central Retina Artery Occlusion
32%
Rat Model
32%
Muskmelon
32%
Gliadin
32%
Superoxide Dismutase
32%
Interleukin 4
32%
Strabismus
32%
Asiatic Acid
32%
Caspase 3
28%
Wound Healing
24%
Diseases
22%
Gelatinase A
21%
Tissue Inhibitor of Metalloproteinase
21%
Hyperglycemia
21%
Phosphate Buffered Saline
19%
Diabetes Mellitus
16%
Retina Macula Cystoid Edema
16%
Eye Injury
15%
Glaucoma
15%
Wound
13%
Anti-Inflammatory Drug
12%
Streptozotocin
10%
Experimental Rabbit
9%